NurExone Biologic Invited to Present Groundbreaking ExoPTEN Therapy at Prestigious September Conferences
23. August 2024 16:03 ET
|
NurExone Biologic Inc
NurExone Biologic to present its innovative ExoPTEN therapy at key September conferences in Boston and New York, showcasing its leadership in regenerative
NurExone Biologic Achieves Key Milestone in Support of Robust Exosome Manufacturing Process
15. August 2024 16:03 ET
|
NurExone Biologic Inc
NurExone’s reliable production from diverse biological sources allows NurExone to optimize exosome production with consistency and efficiency
NurExone's ExoPTEN, loaded with siRNA, Demonstrates Ability to Target Injury and Inflammation Sites – New Study
09. August 2024 16:04 ET
|
NurExone Biologic Inc
NurExone announces promising new data for its ExoPTEN nanodrug, highlighting progress towards commercial-grade manufacturing
NurExone Announces the Transfer of Manufacturing of the Active Element in ExoPTEN Drug to a Commercial GMP Manufacturer
01. August 2024 16:04 ET
|
NurExone Biologic Inc
NurExone Announces the Transfer of Manufacturing of the Active Element in ExoPTEN Drug to a Commercial GMP Manufacturer
NurExone Announces Further Expansion of ExoPTEN Patent Coverage
29. Juli 2024 16:04 ET
|
NurExone Biologic Inc
NurExone Announces Further Expansion of ExoPTEN Patent Coverage in Israel
Updates from NurExone: Growth Conference Presentation and Website Relaunch
05. Juli 2024 08:43 ET
|
NurExone Biologic Inc
TORONTO and HAIFA, Israel, July 05, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company,...
NurExone’s ExoPTEN Being Studied as Glaucoma Treatment for US$3.4 Billion Market
28. Juni 2024 16:04 ET
|
NurExone Biologic Inc
Prestigious Eye Institute Exploring New Indication for NurExone’s ExoPTEN
On Path to First-in-Human Study, NurExone Engages Prominent Expert in Biological Drug Development
21. Juni 2024 16:04 ET
|
NurExone Biologic Inc
TORONTO and HAIFA, Israel, June 21, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company,...
NurExone Announces Expansion of ExoPTEN Patent Coverage with Notice of Allowance for Japanese Patent Application
11. Juni 2024 08:44 ET
|
NurExone Biologic Inc
NurExone Announces Expansion of ExoPTEN Patent Coverage with Notice of Allowance for Japanese Patent Application